Novel Blood Thinner Asundexian Lowers Bleeding Risk in Atrial Fibrillation

New findings from the OCEANIC-AF trial reveal trade-offs between stroke prevention and bleeding risk in treatment-naive patients

Topline:

A new oral blood thinner, asundexian, may reduce bleeding risk in patients with atrial fibrillation who have not previously taken anticoagulants, though it shows a slightly higher rate of stroke compared to apixaban.

Study Details